

**PHESGO**  
**(pertuzumab, trastuzumab, and hyaluronidase-zzxf)**

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 18 years of age or older

### **Diagnoses**

Patient must have **ONE** of the following:

1. Metastatic HER2-positive breast cancer
  - a. Used in combination with docetaxel
  - b. Patient does **NOT** have a history of prior anti-HER2 therapy or chemotherapy for metastatic disease
2. Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early stage breast cancer
  - a. Used in combination with chemotherapy
  - b. Greater than 2 cm in diameter **OR** node positive
3. Adjuvant treatment for HER2-positive early breast cancer
  - a. Used in combination with chemotherapy

**AND ALL** of the following:

- a. HER2 protein overexpression or HER2 gene amplification as confirmed by an FDA-approved test
- b. Left ventricular ejection fraction (LVEF)  $\geq 50\%$
- c. Prescriber agrees to monitor cardiac function and monitor for pulmonary toxicity
- d. **NOT** used intravenously
- e. Will be administered by a healthcare professional
- f. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 7 months after the last dose

## **Prior - Approval Limits**

**Quantity** 4 injections every 84 days

**Duration** 12 months

**PHESGO**  
**(pertuzumab, trastuzumab, and hyaluronidase-zzxf)**

---

## **Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

1. Metastatic HER2-positive breast cancer
  - a. Used in combination with docetaxel
  - b. Left ventricular ejection fraction (LVEF)  $\geq 50\%$
  - c. **NO** disease progression or unacceptable toxicity
  - d. **NOT** used intravenously
  - e. Will be administered by a healthcare professional
  - f. Prescriber agrees to monitor cardiac function and monitor for pulmonary toxicity
  - g. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 7 months after the last dose

## **Prior - Approval *Renewal* Limits**

**Quantity** 4 injections every 84 days

**Duration** 12 months

**NO** renewal for locally advanced, inflammatory or early breast cancer